Guardant Health, Inc.

Health Care
Medical Specialities
www.guardanthealth.com

Safety Score

Market Cap $4.51B
Debt $1.14B
Cash $688.37M
EV $4.96B
FCF -$274.36M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$512.41M
EBIT	-$505.21M
ROA	-33%
FCF	-$274.36M
Equity	-$60.10M
Growth Stability	1
PE	-8.8
PB	-75.04
P/FCF	-16.44
P/S	6.51
Price/Cash	0.15
Debt/Equity	-19
Debt/FCF	-4.16
Net Margins	-61%
Op. Margins	-73%
Sales Growth YoY	34%
Sales Growth QoQ	8%
Sales CAGR	40%
Equity CAGR	-5%
Earnings Growth YoY	25%

Earnings Growth QoQ	5%
Sales CAGR 5Y	26%
Equity CAGR 5Y	-25%
Earnings CAGR 3Y	25%
Sales CAGR 3Y	25%
Equity CAGR 3Y	-23%
Market Cap	$4.51B
Revenue	$692.26M
Assets	$1.54B
Total Debt	$1.14B
Cash	$688.37M
Shares Outstanding	122.32M
EV	4.96B
Safety Score	45%
Working Capital	1.03B
Current Ratio	6.22
Shares Growth 3y	8%
Equity Growth QoQ	4K%
Equity Growth YoY	-126%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

SEC Filings

Direct access to Guardant Health, Inc. (GH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Guardant Health, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Guardant Health, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Guardant Health, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Guardant Health, Inc..

Years

Calculation mode

= -$2.7B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$274M	-$2.7B
DCF		-$249M	-$227M	-$206M	-$187M	-$170M	-$155M	-$141M	-$128M	-$116M	-$106M	-$1.1B
Value	-$2.7B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-183%	-179%	-94%	-35%	-89%	-109%	-146%	-85%	-61%
ROA	-	-	-14%	-7%	-11%	-17%	-34%	-27%	-33%
ROE	-	-	-18%	-9%	-20%	-63%	-1K%	-302%	-

Bad Net Margins (-60.57%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-0	-5.76	-4	-2.94	-3.3	-4.16
Debt over Equity	-	-	-	0	0.62	1.76	18.9	7.18	-19
Growth Stability	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-4.16)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-19)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	97%	82%	137%	34%	30%	20%	25%	26%
Earnings YoY growth	-	93%	-4%	-11%	235%	60%	61%	-27%	-
Equity YoY growth	-	287%	57%	65%	63%	-50%	-91%	164%	-25%
FCF YoY growth	-	105%	17%	-29%	113%	103%	36%	-11%	-